News

Reaffirming Leadership: Medit’s Strong Presence at IDS 2025

COLOGNE, Germany and SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Medit, a global leader in digital dentistry solutions, made…

9 months ago

Guo Guangchang’s Letter to Shareholders: Fosun International Pursues Progress through “Strategic Advancements and Exits”

HONG KONG, March 31, 2025 /PRNewswire/ -- Guo Guangchang, Chairman of Fosun International Limited (HKEX: 0656), issued a letter to…

9 months ago

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As…

9 months ago

Smartee Pioneers a New Phase in Orthodontics with Silicon Valley Founder Mode

SHANGHAI, March 30, 2025 /PRNewswire/ -- As the clear aligner business enters the second quarter of 2025, it shows a promising growth…

9 months ago

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients…

9 months ago

Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk

--Data presented at the American College of Cardiology Annual Scientific Session show that the reduction of bleeding with abelacimab compared…

9 months ago

ProDentim Reviews (EXPOSED): Why 75,000+ Americans Are Replacing Mouthwash with This ProDentim Chewable Tablet

Discover the Oral Probiotic That’s Reshaping Dental Health—Backed by 75,000+ Users and Groundbreaking Science ProDentim reviews ProDentim Official VANCOUVER, WA,…

9 months ago

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic…

9 months ago

NeuroQuiet Reviews (Complaints & Side Effects): Buyers Reveal Unexpected Truths Behind Its Real Effectiveness & Safety

NeuroQuiet Reviews NeuroQuiet VANCOUVER, WA, March 29, 2025 (GLOBE NEWSWIRE) --  NeuroQuiet Reviews In a market flooded with hearing supplements…

9 months ago